UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Trims Stock Holdings in Indivior PLC (NASDAQ:INDV)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of Indivior PLC (NASDAQ:INDV) by 27.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 113,700 shares of the company’s stock after selling 43,394 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned 0.08% of Indivior worth $1,109,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Bank of New York Mellon Corp purchased a new stake in shares of Indivior during the second quarter worth approximately $188,000. VELA Investment Management LLC purchased a new position in shares of Indivior in the 2nd quarter valued at about $235,000. XTX Topco Ltd acquired a new position in Indivior during the second quarter worth about $249,000. Cubist Systematic Strategies LLC increased its holdings in Indivior by 32.0% in the second quarter. Cubist Systematic Strategies LLC now owns 25,236 shares of the company’s stock valued at $407,000 after buying an additional 6,121 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Indivior by 4.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 41,327 shares of the company’s stock valued at $408,000 after acquiring an additional 1,888 shares during the period. 60.33% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

INDV has been the topic of a number of research reports. Piper Sandler restated an “overweight” rating and issued a $16.00 price target (up previously from $15.00) on shares of Indivior in a report on Friday, October 25th. Craig Hallum decreased their price objective on shares of Indivior from $20.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, October 11th.

Indivior Price Performance

INDV stock opened at $11.51 on Thursday. The stock’s 50 day moving average price is $10.07 and its 200 day moving average price is $11.78. The firm has a market cap of $1.59 billion, a P/E ratio of -287.68 and a beta of 0.75. The company has a debt-to-equity ratio of 23.50, a quick ratio of 0.65 and a current ratio of 0.83. Indivior PLC has a 1 year low of $7.33 and a 1 year high of $23.22.

Indivior (NASDAQ:INDV) last announced its earnings results on Thursday, October 24th. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.15. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. The firm had revenue of $307.00 million during the quarter, compared to the consensus estimate of $302.25 million. On average, sell-side analysts expect that Indivior PLC will post 1.68 earnings per share for the current fiscal year.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.